Correction to: Skating on thin ice: Pragmatic prescribing for medication refractory schizophrenia (BMC Psychiatry (2015) 20: 48 DOI: 10.1186/s12888-015-0559-x);Skating on thin ice: Pragmatic prescribing for medication refractory schizophrenia

BMC Psychiatry

Volumn 15, Issue 1, 2015, Pages

  Tracy, Derek K ^a,b   Joyce, Dan W ^b,c   Sarkar, S Neil ^b,d   Mateos Fernandez, Maria Jesus ^b   Shergill, Sukhwinder S ^b,c  

^a OXLEAS NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^d CENTRAL AND NORTH WEST LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Psychosis; Refractory; Schizophrenia; Treatment

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; DROPERIDOL; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM CARBONATE; MELPERONE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; SULPIRIDE; TRIFLUOPERAZINE; VALPROIC ACID; ZUCLOPENTHIXOL; BENZODIAZEPINE DERIVATIVE; SULTOPRIDE;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EXPLORATORY RESEARCH; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MENTAL HEALTH SERVICE; MONOTHERAPY; MULTIVARIATE ANALYSIS; NEUROLOGIC EXAMINATION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRESCRIPTION; PSYCHIATRIST; PSYCHOLOGICAL REFRACTORY PERIOD; REFRACTORY SCHIZOPHRENIA; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SKATING; SYMPTOM; TERTIARY HEALTH CARE; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; MIDDLE AGED; PSYCHOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; QUETIAPINE FUMARATE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SULPIRIDE; VALPROIC ACID;

EID: 84937810710     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-019-2155-y     Document Type: Erratum

References (27)

1. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2-44.
2. Jaaskelainen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39(6):1296-306.
3. Rowe AR, Mercer L, Casetti V, Sendt K-V, Giaroli G, Shergill SS, et al. Dementia praecox redux: a systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia. J Psychopharmacol. 2015;29(2):197-211.
4. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-62.
5. Chakos M, Lieberman J, Hoffman E, Bradford D, Schumann G. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001;158(4):518-26.
6. Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. 2009;1:CD000059.
7. Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry. 2001;58(10):965-72.
8. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry. 1994;151(12):1744-52.
9. Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ, Okasha A, Singh B, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res. 2008;100(1-3):20-38.
10. Taylor DM, Smith L, Gee SH, Nielsen J. Augmentation of clozapine with a second antipsychotic - a meta-analysis. Acta Psychiatr Scand. 2012;125(1):15-24.
11. Tracy DK, Sendt K-V, Shergill SS. Antipsychotic polypharmacy: still dirty, but hardly a secret. A systematic review and clinical guide. Current Psychopharmacology. 2013;2(2):143-71.
12. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318-78.
13. NICE, Core interventions in the treatment and management of schizophrenia in primary and secondary care (update), 2009, London, UK: National Institute for Health and Care Excellence.
14. Taylor D, Paton C, Kapur S. Prescribing Guidelines in Psychiatry. 11 ed, ed. D. Taylor, C. Paton, and S. Kapur. 2012, London, UK: Wiley-Blackwell
15. Tracy DK, Shergill SS. Treatment-Refractory Schizophrenia: definition and assessment. In: Gaughran F, Buckley PF, editors. Treatment Refractory Schizophrenia: a clinical conundrum. Berlin: Springer; 2014.
16. Harrison GHopper K, Craig T, Laska E, Siegel C, Wanderling J, et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry. 2001;178:506-17.
17. Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry. 2014;14:102.
18. Berkowitz RL, Patel U, Ni Q, Parks JJ, Docherty JP. The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state. J Clin Psychiatry. 2012;73(4):498-503.
19. DoH, NHS Specialised Services. Definition no 22. Specialised mental health services (all ages). London, UK: D.o. Health; 2009.
20. Sarkar SN, Tracy DK, Fernandez M-JM, Nalesnik N, Dhillon G, Onwumere J, et al. Unheard voices: outcomes of tertiary care for treatment-refractory psychosis. The Psychiatric Bulletin, 2014; 38:71-74.
21. Brittain PJ, Stahl D, Rucker J, Kawadler J, Schumann G. A review of the reliability and validity of OPCRIT in relation to its use for the routine clinical assessment of mental health patients. Int J Methods Psychiatr Res. 2013;22(2):110-37.
22. McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry. 1991;48(8):764-70.
23. Pagel T, Baldessarini RJ, Franklin J, Baethge C. Characteristics of patients diagnosed with schizoaffective disorder compared with schizophrenia and bipolar disorder. Bipolar Disord. 2013;15(3):229-39.
24. Tukey JW. Exploratory Data Analysis. 1977, New York, USA: Pearson.
25. Mihalopoulos C, McGorry P, Roberts S, McFarlane C. The procedural validity of retrospective case note diagnosis. Aust N Z J Psychiatry. 2000;34(1):154-9.
26. Sendt KV, Tracy DK, Bhattacharyya S. A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res. 2015;225(1-2):14-30.
27. Howes OD, Verqunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012;201(6):481-5.